# 4D pharma plc Publication on human gut microbiota potential to serve as therapeutic inhibitors

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-publication-human-gut-microbiota-potential-serve-therapeutic-inhibitors/412755690
- Published: 2018-07-30T07:08:06+01:00
- Author: Giles Arbor

**4D pharma plc** (LON:DDDD), a pharmaceutical company leading the development of
live biotherapeutics, today announces the publication of data showing that specific
single bacterial strains from the human gut microbiota have the potential to serve
as therapeutic inhibitors of the human enzyme histone deacetylase (HDAC), which 
is particularly relevant for disease areas involving host epigenetic aberrations.

The paper, titled “Human gut bacteria as potent class I histone deacetylase inhibitors
in vitro through production of butyric acid and valeric acid” (Yuille S., et al)
is published in PLOS ONE, the peer-reviewed open access scientific journal.

Overexpression of isoforms of HDAC has been implicated in a variety of diseases,
including cancer, colitis, cardiovascular disease and neurodegeneration. HDAC inhibitors
have a long history as therapeutic targets and the gut microbiota is known to have
an influence on HDAC activity via microbial-derived metabolites. In this study, 
researchers used an in vitro approach to screen the 4D bacterial library to identify
strains which inhibit different HDAC isoforms. One identified strain, MRx0029, was
added to a model microbial consortium to assess its metabolic activity in interaction
with a complex bacterial community. They found that MRx0029 successfully established
in the consortium and enhanced the total and specific HDAC inhibitory function by
increasing the capacity of the community to produce butyrate and valeric acid.

> **Dr. Alex Stevenson, 4D Pharma plc Chief Scientific Officer, commented:** “This
> work shows that microbiome-derived live biotherapeutics can inhibit specific HDAC
> activity via previously unknown mechanisms. This could lead to new live biotherapeutic
> therapies targeting this class of enzymes for conditions including cancer, neurodegenerative
> disorders and inflammatory pathologies. Moreover, in developing a model microbiome
> consortium, we have further demonstrated the ability of single-strain live biotherapeutics
> to induce community-wide functional changes in the microbiome and impact disease-
> relevant host signaling pathways.”

Share on:
